logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Chd1 Loss Reprograms Srebp2driven Cholesterol Synthesis To Fuel Androgenresponsive Growth And Castration Resistance In Spopmutated Prostate Tumors Feiyu Chen Haoyan Li Yin Wang Ximing Tang Kevin Lin Qidong Li Chenling Meng Wei Shi Javier Leo Xin Liang Jie Zhang Vivien Van Iqbal Mahmud Bo Wei Philip L Lorenzi Maria G Raso Ana Aparicio Yue Lu Daniel E Frigo

  • SKU: BELL-237766730
Chd1 Loss Reprograms Srebp2driven Cholesterol Synthesis To Fuel Androgenresponsive Growth And Castration Resistance In Spopmutated Prostate Tumors Feiyu Chen Haoyan Li Yin Wang Ximing Tang Kevin Lin Qidong Li Chenling Meng Wei Shi Javier Leo Xin Liang Jie Zhang Vivien Van Iqbal Mahmud Bo Wei Philip L Lorenzi Maria G Raso Ana Aparicio Yue Lu Daniel E Frigo
$ 35.00 $ 45.00 (-22%)

4.4

72 reviews

Chd1 Loss Reprograms Srebp2driven Cholesterol Synthesis To Fuel Androgenresponsive Growth And Castration Resistance In Spopmutated Prostate Tumors Feiyu Chen Haoyan Li Yin Wang Ximing Tang Kevin Lin Qidong Li Chenling Meng Wei Shi Javier Leo Xin Liang Jie Zhang Vivien Van Iqbal Mahmud Bo Wei Philip L Lorenzi Maria G Raso Ana Aparicio Yue Lu Daniel E Frigo instant download after payment.

Publisher: x
File Extension: PDF
File size: 21.96 MB
Author: Feiyu Chen & Haoyan Li & Yin Wang & Ximing Tang & Kevin Lin & Qidong Li & Chenling Meng & Wei Shi & Javier Leo & Xin Liang & Jie Zhang & Vivien Van & Iqbal Mahmud & Bo Wei & Philip L. Lorenzi & Maria G. Raso & Ana Aparicio & Yue Lu & Daniel E. Frigo &...
Language: English
Year: 2025

Product desciption

Chd1 Loss Reprograms Srebp2driven Cholesterol Synthesis To Fuel Androgenresponsive Growth And Castration Resistance In Spopmutated Prostate Tumors Feiyu Chen Haoyan Li Yin Wang Ximing Tang Kevin Lin Qidong Li Chenling Meng Wei Shi Javier Leo Xin Liang Jie Zhang Vivien Van Iqbal Mahmud Bo Wei Philip L Lorenzi Maria G Raso Ana Aparicio Yue Lu Daniel E Frigo by Feiyu Chen & Haoyan Li & Yin Wang & Ximing Tang & Kevin Lin & Qidong Li & Chenling Meng & Wei Shi & Javier Leo & Xin Liang & Jie Zhang & Vivien Van & Iqbal Mahmud & Bo Wei & Philip L. Lorenzi & Maria G. Raso & Ana Aparicio & Yue Lu & Daniel E. Frigo &... instant download after payment.

Nature Cancer, doi:10.1038/s43018-025-00952-z

Despite undergoing castration, most individuals with prostate cancer (PCa) experience progression to castration-resistant PCa (CRPC), in which the androgen receptor (AR) remains an important driver. Concurrent genetic alterations in SPOP and CHD1 defne a unique subtype of PCa, but their interactions in tumor progression and therapy response remain unclear. Here, we provide genetic evidence supporting that CHD1 loss accelerates disease progression and confers resistance to castration in males with SPOP-mutated PCa. By leveraging genetic engineering and multiomics, we uncovered a noncanonical function of CHD1 in lipid metabolism reprogramming via repressing the SREBP2 transcriptome. Loss of CHD1 induces cholesterol production, supplies intratumoral androgen biosynthesis and enhances AR activity, leading to castration resistance of SPOP-mutated PCa. Combining anti-androgen therapy with cholesterol-lowering drugs showed synergistic and durable activity against CRPC harboring CHD1 loss and SPOP mutations. These fndings advance our understanding of an emerging PCa subtype and ofer biomarker-driven combinatorial treatment strategies for men with CRPC.

Related Products